Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2007

View Archived Issues

Study reveals advantages of insulin VIAject over insulin lispro, regular insulin

Tetrodotoxin relieves severe cancer-related pain

UK-500,001 ineffective in asthma, COPD studies

Inhibition of MarA virulence factor increases survival in Pseudomonas aeruginosa pneumonia model

Incyte provides update on positive proof-of-concept results from pipeline

NPS licenses rights to Gattex outside of North America to Nycomed

CombinatoRx begins CRx-102 phase IIb clinical study in knee osteoarthritis

Asentar enters phase II trial in pancreatic cancer and is in ongoing phase III AIPC trial

Series A financing raises USD 20 million for Sequel

OctoPlus acquires worldwide rights to Theratechnologies' GLP-1 analogues

Positive results for SIGA's preclinical trials of ST-246 for smallpox

NexGenix signs worldwide Hsp90 inhibitors agreement with the ULP and CNRS

Palatin provides update on phase II trial of bremelanotide for FSAD

The Medicines Company's sNDA for expanded use of Angiomax accepted by FDA

Update on EMEA submission for Rapinyl for breakthrough cancer pain

Santhera to initiate phase III trial of SNT-MC17 under SPA with FDA

Biomira changes name to Oncothyreon

Preclinical results of VEL-0230, a dual-action cathepsin K inhibitor, reported

Positive preclinical results of the anti-varicella zoster virus agent FV-100

Basilea submits MAA to Swissmedic for oral alitretinoin for CHE

Tanabe Seiyaku and Mitsubishi Pharma merge to form Mitsubishi Tanabe Pharma

FDA approves CSL's influenza vaccine Afluria

EC expands indication of Amgen's Aranesp

Recent patents impart new therapeutic agents for cancer

Once-daily oral antihistamine Xyzal available by prescription in U.S.

New antipsoriatic agents reported by Wisconsin Alumni Research Foundation

Novel histamine H3 receptor ligands reported in recent Abbott patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...